Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN (DIA-RAMADAN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with type 2 diabetes observing fast during Ramadan
Informed consent obtained before any trial-related activities
Male or female type 2 diabetic patients aged >18 years
Patients with controlled or suboptimal controlled type 2 diabetes
Patients with experience in SMBG controlling using glucometer
Patients who are willing to fast during Ramadan
Patients already treated with Gliclazide MR 60mg
Insulin therapy requirement
Severe liver or renal failure
HbA1c ≥ 9%
Contraindication to gliclazide according to SmPC
Pregnancy or breast feeding
Previous experience of severe or repeated hypoglycemia events without triggered factor within the previous year